<abstract xmlns="http://www.w3.org/1999/xhtml">

<sec id="j_raon-2023-0006_s_009"><h3>Background</h3>
<p>Pancreatic islet transplantation via infusion through the portal vein, has become an established clinical treatment for patients with type 1 diabetes. Because the engraftment efficiency is low, new approaches for pancreatic islets implantation are sought. The goal of this study is to explore the possibility that a non-thermal irreversible electroporation (NTIRE) decellularized matrix in the liver could be used as an engraftment site for pancreatic islets.</p></sec>
<sec id="j_raon-2023-0006_s_010"><h3>Materials and methods</h3>
<p>Pancreatic islets or saline controls were injected at sites pre-treated with NTIRE in the livers of 7 rats, 16 hours after NTIRE treatment. Seven days after the NTIRE treatment, islet graft function was assessed by detecting insulin and glucagon in the liver with immunohistochemistry.</p></sec>
<sec id="j_raon-2023-0006_s_011"><h3>Results</h3>
<p>Pancreatic islets implanted into a NTIRE-treated volume of liver became incorporated into the liver parenchyma and produced insulin and glucagon in 2 of the 7 rat livers. Potential reasons for the failure to observe pancreatic islets in the remaining 5/7 rats may include local inflammatory reaction, graft rejection, low numbers of starting islets, timing of implantation.</p></sec>
<sec id="j_raon-2023-0006_s_012"><h3>Conclusions</h3>
<p>This study shows that pancreatic islets can become incorporated and function in an NTIRE-generated extracellular matrix niche, albeit the success rate is low. Advances in the field could be achieved by developing a better understanding of the mechanisms of failure and ways to combat these mechanisms.</p></sec>
</abstract>

Background
Pancreatic islet transplantation via infusion through the portal vein, has become an established clinical treatment for patients with type 1 diabetes. Because the engraftment efficiency is low, new approaches for pancreatic islets implantation are sought. The goal of this study is to explore the possibility that a non-thermal irreversible electroporation (NTIRE) decellularized matrix in the liver could be used as an engraftment site for pancreatic islets.
Materials and methods
Pancreatic islets or saline controls were injected at sites pre-treated with NTIRE in the livers of 7 rats, 16 hours after NTIRE treatment. Seven days after the NTIRE treatment, islet graft function was assessed by detecting insulin and glucagon in the liver with immunohistochemistry.
Results
Pancreatic islets implanted into a NTIRE-treated volume of liver became incorporated into the liver parenchyma and produced insulin and glucagon in 2 of the 7 rat livers. Potential reasons for the failure to observe pancreatic islets in the remaining 5/7 rats may include local inflammatory reaction, graft rejection, low numbers of starting islets, timing of implantation.
Conclusions
This study shows that pancreatic islets can become incorporated and function in an NTIRE-generated extracellular matrix niche, albeit the success rate is low. Advances in the field could be achieved by developing a better understanding of the mechanisms of failure and ways to combat these mechanisms.

Pancreatic islets implanted in an irreversible electroporation generated extracellular matrix in the liver

Radiology and Oncology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Background
Pancreatic islet transplantation via infusion through the portal vein, has become an established clinical treatment for patients with type 1...

Pancreatic islets implanted in an irreversible electroporation generated extracellular matrix in the liver

Article Category: Research Article

Publié en ligne: 19 janv. 2023

Pages: 51 - 58

Reçu: 05 nov. 2022

Accepté: 24 nov. 2022

DOI: https://doi.org/10.2478/raon-2023-0006

© 2023 Yanfang Zhang, Yanpeng Lv, Yunlong Wang, Tammy T Chang, Boris Rubinsky, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.